Sensorion SA
PAR:ALSEN
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Sensorion SA
Accounts Payable
Sensorion SA
Accounts Payable Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Accounts Payable | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Sensorion SA
PAR:ALSEN
|
Accounts Payable
€5.6m
|
CAGR 3-Years
-9%
|
CAGR 5-Years
20%
|
CAGR 10-Years
27%
|
|
|
Valneva SE
PAR:VLA
|
Accounts Payable
€9.1m
|
CAGR 3-Years
-40%
|
CAGR 5-Years
-24%
|
CAGR 10-Years
-2%
|
|
|
G
|
Genfit SA
PAR:GNFT
|
Accounts Payable
€26.4m
|
CAGR 3-Years
45%
|
CAGR 5-Years
5%
|
CAGR 10-Years
17%
|
|
|
Inventiva SA
PAR:IVA
|
Accounts Payable
€34.7m
|
CAGR 3-Years
21%
|
CAGR 5-Years
38%
|
CAGR 10-Years
N/A
|
|
|
DBV Technologies SA
PAR:DBV
|
Accounts Payable
$40.9m
|
CAGR 3-Years
41%
|
CAGR 5-Years
15%
|
CAGR 10-Years
15%
|
|
|
Abivax SA
PAR:ABVX
|
Accounts Payable
€43.8m
|
CAGR 3-Years
41%
|
CAGR 5-Years
20%
|
CAGR 10-Years
32%
|
|
Sensorion SA
Glance View
Sensorion SAS is a biopharmaceutical company, which engages in the development of therapies to treat and prevent diseases of the inner ear such as deafness, vertigo and tinnitus. The company is headquartered in Montpellier, Occitanie and currently employs 34 full-time employees. The company went IPO on 2015-04-21. The firm is principally active in the development of targeted therapeutic solutions to treat inner ear diseases. The firm develops also drug treatments, from molecular biology all the way to animal pharmacology, toxicology, and clinical research and therapeutic solutions to treat vestibular deficits. Sensorion SA is a spin-off of the research team Pathophysiology and Therapy of Vestibular Deficits in Montpellier Neuroscience Institute.
See Also
What is Sensorion SA's Accounts Payable?
Accounts Payable
5.6m
EUR
Based on the financial report for Dec 31, 2025, Sensorion SA's Accounts Payable amounts to 5.6m EUR.
What is Sensorion SA's Accounts Payable growth rate?
Accounts Payable CAGR 10Y
27%
Over the last year, the Accounts Payable growth was -19%. The average annual Accounts Payable growth rates for Sensorion SA have been -9% over the past three years , 20% over the past five years , and 27% over the past ten years .
